source
- US panel warns China’s biotech plan could dominate sector and threaten drug supply chainA congressional commission has warned that China’s new five-year biotech plan could allow it to dominate the global drug market. The commission says the strategy could leave U.S. patients vulnerab…
- FDA approves Regeneron's Livsayis, first RNAi therapy for generalized myasthenia gravisThe Food and Drug Administration approved Regeneron's Livsayis, an RNA interference drug for generalized myasthenia gravis, marking the company's first marketed RNAi therapy. The drug, originally…